Agreed, I think an expansion in the indication for use to include closed angle is a potentially major catalyst for further revenue growth (I wonder if they're currently seeking this as part of the existing China FDA approval application?). It's still a very large market, but much less developed in terms of treatment options. We won't be competing against any other MIGS devices, when a doctor is presented with a closed angle case iTrack Advance will be the first and only device they think of. Hopefully the China approval comes quick, I have a feeling that's going to grow into a major market for this company over the next few years.
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-351
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $44.66M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $9.907K | 50.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 65104 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 51773 | 2 |
View Market Depth
| Last trade - 13.43pm 13/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |